A Phase 2 interventional study of RGT001-075 and Placebo in Type 2 Diabetes Mellitus, sponsored by Regor Pharmaceuticals Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Regor Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,305 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,305 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,595th largest by enrollment of the 2,958 interventional ones that give a count, is one of 148 that started in 2022, is one of 391 in phase 2, and was the 2,633rd registered.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →343 of the 3,305 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Pfizer · Sites in United States
Ages 18+
Rahul Sachdeva · Sites in United States
Ages 18+ · Healthy volunteers
Amgen · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,305 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 424 · Phase 2 465 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 148 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 91 across the 2,958 interventional studies, 128 across the 336 observational. Of the 2,649 that completed or were terminated, 1,165 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,487 of 3,305 have an industry lead sponsor. The 10 most frequent:
Regor Pharmaceuticals Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Regor Pharmaceuticals Inc. has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
187 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 187 to your calendar (.ics) → With an account.
Among the 3,305 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: RGT001-075
Drug: RGT001-075
Drug: RGT001-075
Drug: RGT001-075
Drug: RGT001-075
Drug: RGT001-075
Other: Placebo
Oral GLP1 Receptor Agonist
Placebo comparator
Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population
Time frame: up to 16 weeks
Change in fasting plasma glucose from baseline to end of treatment in the modified intent-to-treat population
Time frame: up to 16 weeks
Change in mean body weight (absolute and %) from baseline to end of treatment in the modified intent-to-treat population
Time frame: up to 16 weeks
Change in body mass index from baseline to end of treatment in the modified intent-to-treat population
Time frame: up to 16 weeks
Change in waist circumference from baseline to end of treatment in the modified intent-to-treat population
Time frame: up to 16 weeks
Change in mean blood lipids including triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) from baseline to end of treatment in the modified intent-to-treat population
Time frame: up to 16 weeks
Percentages of patients achieving HbA1c <6.0%, <6.5%, and/or <7.0%
Time frame: up to 16 weeks
Percentages of patients achieving ≥5% and/or ≥10% greater body weight loss
Time frame: up to 16 weeks
Incidence of treatment-emergent adverse events (TEAE)s, serious adverse events (SAE)s, deaths, and adverse events (AE)s leading to study discontinuation
Time frame: up to 16 weeks
Vital signs - Systolic blood pressure (mmHg) absolute change from baseline
Time frame: up to 16 weeks
Vital signs - Diastolic blood pressure (mmHg) absolute change from baseline
Time frame: up to 16 weeks
Vital signs - Heart rate (beats/minute) absolute change from baseline
Time frame: up to 16 weeks
Vital signs - Body weight (kg) absolute and percent change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - complete blood count absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum sodium absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum potassium absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum total bilirubin absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum direct bilirubin absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum alkaline phosphatase absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum alanine aminotransferase absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum aspartate aminotransferase absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum blood urea nitrogen absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum creatinine absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum uric acid absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum calcium absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum lipase absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum amylase absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - eGFR (calculated) absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - fasting serum glucose absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum albumin absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum total protein absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - fasting serum total cholesterol absolute change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - fasting serum triglycerides absolute and percent change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - fasting serum HDL-C absolute and percent change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - fasting serum LDL-C absolute and percent change from baseline
Time frame: up to 16 weeks
Safety clinical laboratories - serum calcitonin absolute change from screening
Time frame: up to 16 weeks
ECG interval change from baseline absolute and categorical outliers >450ms
Time frame: up to 16 weeks
Proportion of patients who report AEs of Special Interest (AESI) including GI intolerability, hypoglycemia, drug hypersensitivity reactions, acute pancreatitis, thyroid C-cell hyperplasia and C-cell neoplasms, and cardiovascular (CV) events
Time frame: up to 16 weeks
Ran from Mar 2022 to primary completion in May 2023, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RGT001-075
Regor Pharmaceuticals Inc.